What is the CVSS score of CVE-2023-38958?

CVE-2023-38958 has a CVSS 3.1 base score of 5.3 (Medium). CVSS vector: CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:N. EPSS exploitation probability: 0.3%.

Bioaccess Ivs CVE-2023-38958

MEDIUM

Incorrect Authorization (CWE-863)

2023-08-03 cve@mitre.org

Authentication Bypass Bioaccess Ivs

5.3

CVSS 3.1 · NVD

Severity by source

NVD PRIMARY

5.3 MEDIUM

AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:N

Primary rating from NVD · only source for this CVE.

CVSS VectorNVD

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:N

Attack Vector

Network

Attack Complexity

Low

Privileges Required

None

User Interaction

None

Scope

Unchanged

Confidentiality

None

Integrity

Low

Availability

None

Lifecycle Timeline

CVE Published

Aug 03, 2023 - 02:15 nvd

MEDIUM 5.3

DescriptionNVD

An access control issue in ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to arbitrarily close and open the doors managed by the platform remotely via sending a crafted web request.

AnalysisAI

An access control issue in ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to arbitrarily close and open the doors managed by the platform remotely via sending a crafted web request. Rated medium severity (CVSS 5.3), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.

Technical ContextAI

This vulnerability is classified as Incorrect Authorization (CWE-863), which allows attackers to bypass authorization checks to access restricted resources. An access control issue in ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to arbitrarily close and open the doors managed by the platform remotely via sending a crafted web request. Affected products include: Zkteco Bioaccess Ivs.

RemediationAI

No vendor patch is available at time of analysis. Monitor vendor advisories for updates. Review and test authorization logic, implement consistent access control checks, use centralized authorization framework.